-
ESTIMATING THE PREVALENCE OF TREATMENT RESISTANT DEPRESSION AND COMPARING HEALTHCARE RESOURCE UTILISATION USING LINKED PRIMARY CARE AND PSYCHIATRIC SECONDARY CARE ELECTRONIC HEALTH RECORDS IN ENGLAND
Aug 11, 2026, 17:16 PM -
USE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING (AI/ML) IN HEALTH TECHNOLOGY ASSESSMENT (HTA) EVIDENCE GENERATION: A LANDSCAPE REVIEW OF HTA GUIDANCE AND EMERGING STANDARDS
Aug 11, 2026, 17:16 PM -
ARE EU JOINT CLINICAL ASSESSMENTS (JCA) BASED ON OUTDATED EVIDENCE? TRACKING EVIDENCE EVOLUTION DURING ACTIVE JCAS USING REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEWS (REAL-SLRS)
Aug 11, 2026, 17:16 PM -
POST-REGISTRATION STUDIES IN FRANCE : A SYSTEMATIC REVIEW OF THE HAUTE AUTORITE DE SANTE TRANSPARENCY COMMITTEE'S REASSESSMENTS (2023-2026)
Aug 11, 2026, 17:16 PM -
DUTCH ACCESS TO ONCOLOGY MEDICINES IN A EUROPEAN CONTEXT
Aug 11, 2026, 17:16 PM -
GETTING AHEAD OF THE JCA: A TIERED COUNTRY PRIORITIZATION FRAMEWORK FOR PREDICTIVE PICO SCOPING
Aug 11, 2026, 17:16 PM -
HEALTH AND ECONOMIC IMPACT OF INCREASING ENTERAL NUTRITION USE IN CRITICALLY ILL PATIENTS: DEVELOPMENT OF A HOSPITAL-BASED VALUE COMMUNICATION TOOL IN ITALY
Aug 11, 2026, 17:16 PM -
ANALYSIS OF HTA OUTCOMES OF EMA PRIME DESIGNATED DRUGS IN GERMANY AND THE UK
Aug 11, 2026, 17:16 PM -
THE 2025 TURNING POINT IN CEESP OPINION INVALIDATIONS: INSIGHTS FROM A QUALITATIVE ANALYSIS OF COMMITTEE DELIBERATIONS
Aug 11, 2026, 17:16 PM -
ECONOMIC BURDEN OF PREMATURE MORTALITY ASSOCIATED WITH FOUR MAJOR CANCERS IN FRANCE, 2014-2023
Aug 11, 2026, 17:16 PM -
APPLYING THE GENERALIZED RISK-ADJUSTED COST-EFFECTIVENESS FRAMEWORK TO DERIVE WILLINGNESS-TO-PAY THRESHOLDS FOR ER+/HER2-/ESR1+ METASTATIC BREAST CANCER
Aug 11, 2026, 17:16 PM -
VENTURE-1: IMPACT OF VK2735, A DUAL INCRETIN AGONIST, ON PREDICTED CARDIOVASCULAR DISEASE RISK
Aug 11, 2026, 17:16 PM -
THE BURDEN OF RESPIRATORY SYNCYTIAL VIRUS IN TURKIYE: FINDINGS FROM A PATIENT SURVEY ON AWARENESS, DISEASE EXPERIENCE, AND IMMUNIZATION ATTITUDES
Aug 11, 2026, 17:16 PM -
SYSTEMATIC LITERATURE REVIEW OF ADVERSE EVENTS OBSERVED IN THE REAL WORLD WITH ISAVUCONAZOLE, VORICONAZOLE AND LIPOSOMAL AMPHOTERICIN B IN INVASIVE MOLD INFECTION TREATMENTAND LIPOSOMAL AMPHOTERICIN B IN INVASIVE MOLD INFECTION TREATMENT
Aug 11, 2026, 17:16 PM -
COMPARISON OF VALUE ESTIMATED USING TIME TRADE OFF AND WILLINGNESS TO PAY IN THE TREATMENT OF X-LINKED HYPOPHOSPHATEMIA
Aug 11, 2026, 17:16 PM -
BIOSIMILAR-ENABLED ACCESS AND REPOSITIONING (BEAR): A FRAMEWORK FOR LIFECYCLE ASSESSMENT AND REPOSITIONING OF BIOLOGIC THERAPIES INFORMED BY CROSS-COUNTRY EVIDENCE AND STAKEHOLDER RECOMMENDATIONS
Aug 11, 2026, 17:16 PM -
BEYOND PATIENT OUTCOMES: THE GROWING RECOGNITION OF CAREGIVER IMPACT IN OUTCOMES RESEARCH
Aug 11, 2026, 17:16 PM -
A SCENARIO-BASED SIMULATION FRAMEWORK TO BRIDGE EFFICACY TO REAL-WORLD EFFECTIVENESS FOR NEWLY APPROVED THERAPIES
Aug 11, 2026, 17:16 PM -
SOCIETAL IMPACT OF DIABETIC MACULAR EDEMA TREATMENT IN MOROCCO: A DISEASE-LEVEL SOCIAL IMPACT ASSESSMENT USING A HUMAN CAPITAL APPROACH
Aug 11, 2026, 17:16 PM -
EPIDEMIOLOGY OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) AMONG ADULTS IN SPAIN: A SYSTEMATIC REVIEW, META-ANALYSIS AND FUTURE PROJECTIONS
Aug 11, 2026, 17:16 PM
